loader from loading.io

Episode 350: Breast Cancer Treatment Considerations for Nurses

The ONS Podcast

Release Date: 02/14/2025

Episode 353: ONS 50th Anniversary: Evolution of Oncology Nursing Certification show art Episode 353: ONS 50th Anniversary: Evolution of Oncology Nursing Certification

The ONS Podcast

“The response was, in my opinion, sort of overwhelmingly positive. I think all of us old-timers who were at ONS Congress® in 1986 remember those 1,600 nurses waiting in line to enter the ballroom to take that inaugural exam. It takes a while to check in 1,600 people. They kind of all filled up the lobby outside of the ballroom, and then they spilled over down into the escalator, and the escalators had to be turned off,” Cyndi Miller-Murphy, MSN, FAAN, CAE, first executive director of the Oncology Nursing Certification Corporation (ONCC), told Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, ONS...

info_outline
Episode 352: Pharmacology 101: Epigenetics show art Episode 352: Pharmacology 101: Epigenetics

The ONS Podcast

“Now, what we found is that epigenetics is actually heritable and it’s actually reversible. And we can now manipulate these principles with pharmacotherapy drugs,” Eric Zack, RN, OCN®, BMTCN®, clinical assistant professor at Loyola College Chicago Marcella Niehoff School of Nursing in Chicago, IL, and RN3 at Rush University Medical Center in Chicago, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the epigenetics drug class.  Music Credit: “” by Kevin MacLeod  Licensed under Creative Commons by...

info_outline
Episode 351: What It’s Like to Develop Symptom Intervention Resources show art Episode 351: What It’s Like to Develop Symptom Intervention Resources

The ONS Podcast

“It is very much a collaborative group process. There are group meetings where we come to consensus on our different ratings. There’s so much support from ONS staff, even amongst our different groups, even when you’re assigned to one peer reviewer. Let’s say you go on vacation, sometimes we’re paired with other people, too. So there is some flexibility in the opportunity as well,” Holly Tenaglia, DNP, APRN, AGCNS-BC, OCN®, lecturer at Old Dominion University in Norfolk, VA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a...

info_outline
Episode 350: Breast Cancer Treatment Considerations for Nurses show art Episode 350: Breast Cancer Treatment Considerations for Nurses

The ONS Podcast

“This is what totally drives the treatment decisions, and that’s why having that pathology report when the nurse is educating the patient is so important, because you can say, well, you have this kind of breast cancer, and this kind of breast cancer is generally treated this way,” Suzanne Mahon, DNS, RN, AOCN®, AGN-BC, FAAN, professor emeritus at Saint Louis University in Missouri, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about what oncology nurses need to know about breast cancer treatment.  Music Credit:...

info_outline
Episode 349: ONS 50th Anniversary: Evolution of Safe Handling and ONS’s Legacy in Developing Safe Handling Guidelines show art Episode 349: ONS 50th Anniversary: Evolution of Safe Handling and ONS’s Legacy in Developing Safe Handling Guidelines

The ONS Podcast

“What I find most rewarding is connecting with nurses, who now understand the risks of exposure and are committed to minimizing their personal exposure. When I first started speaking about safe handling, there were a lot of nurses who were skeptical about the need for self-protection. I rarely see that now. Nurses are concerned for their own safety and more open to protective behaviors,” ONS member Martha Polovich, PhD, RN, AOCN®-Emeritus, adjunct professor in the School of Medicine at the University of Maryland, told Liz Rodriguez, DNP, RN, OCN®, CENP, ONS member and 50th anniversary...

info_outline
Episode 348: Breast Cancer Diagnostic Considerations for Nurses show art Episode 348: Breast Cancer Diagnostic Considerations for Nurses

The ONS Podcast

“We know that some women are going to get called back. And it’s just because usually they can’t see something clearly enough. And so in most cases, those women are going to get cleared with one or two images, and they’re going to say, ‘Oh, we compressed that better, we checked it with an ultrasound, we’re fine.’ That woman can go ahead and go. But we don’t want to miss those early breast cancers,” Suzanne Mahon, DNS, RN, AOCN®, AGN-BC, FAAN, professor emeritus at Saint Louis University in Missouri, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing...

info_outline
Episode 347: Care Considerations for Radiopharmaceuticals and Theranostics in Patients With Cancer show art Episode 347: Care Considerations for Radiopharmaceuticals and Theranostics in Patients With Cancer

The ONS Podcast

"If you take your normal radiation oncology experience, as we know in radiation oncology, radiations are done by the machines, you know, externally. Nurses deal with the side effects and everything like that, whereas radiopharmaceuticals are given kind of on the internal basis, they’re systemic,” ONS member John Hollman, BSN, RN, OCN®, radiation nurse educator for Texas Oncology, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about caring for patients receiving radiopharmaceuticals and theranostics.  Music Credit:...

info_outline
Episode 346: Pharmacology 101: BTK Inhibitors show art Episode 346: Pharmacology 101: BTK Inhibitors

The ONS Podcast

"In B cell malignancies, BTKi inhibits that BTK enzyme which is very upstream. It tells NF-κB to stop signaling into the nucleus and then inhibits proliferation and survival of B cells,"  Puja Patel, PharmD, BCOP, clinical oncology pharmacist at Northwestern Medicine Cancer Center at Delnor Hospital in Geneva, IL, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about BTK inhibitors.  Music Credit: “” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 1.0 contact hours of...

info_outline
Episode 345: Breast Cancer Screening, Detection, and Disparities show art Episode 345: Breast Cancer Screening, Detection, and Disparities

The ONS Podcast

“The statistic you always kind of want to keep in the back of your brain is that over a lifetime, one in eight women will be diagnosed with breast cancer. So that means for an individual assigned female at birth, there’s a 13% chance that if that individual lives to age 85, that they will be diagnosed with breast cancer. So, it’s the most common cancer diagnosed in this group,” Suzanne Mahon, DNS, RN, AOCN®, AGN-BC, FAAN, professor emeritus at Saint Louis University in St. Louis, MO, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a...

info_outline
Episode 344: ONS 50th Anniversary: Founding Leaders’ Vision and Challenges, Then and Now show art Episode 344: ONS 50th Anniversary: Founding Leaders’ Vision and Challenges, Then and Now

The ONS Podcast

“Who would think that we would be here 50 years later? And with the excitement that I think will build even more, I’m so humbled and honored to talk to young nurses. And their excitement—the same excitement that we had in the very beginning—is inherent. I hope that our legacy will be that we are able to pass on this tremendous gift of our careers to new nurses,” Cindi Cantril, MPH, RN, OCN®-Emeritus, founding ONS member and first vice president, told Darcy Burbage, DNP, RN, AOCN®, CBCN®, chair of the ONS 50th Anniversary Committee, during a conversation about the history of...

info_outline
 
More Episodes

“This is what totally drives the treatment decisions, and that’s why having that pathology report when the nurse is educating the patient is so important, because you can say, well, you have this kind of breast cancer, and this kind of breast cancer is generally treated this way,” Suzanne Mahon, DNS, RN, AOCN®, AGN-BC, FAAN, professor emeritus at Saint Louis University in Missouri, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about what oncology nurses need to know about breast cancer treatment. 

Music Credit: “Fireflies and Stardust” by Kevin MacLeod 

Licensed under Creative Commons by Attribution 3.0  

Earn 1.0 contact hours (including 15 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 14, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. 

Learning outcome: Learners will report an increase in knowledge related to breast cancer treatment considerations. 

Episode Notes  

To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  

To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library

To provide feedback or otherwise reach ONS about the podcast, email [email protected]


Highlights From This Episode 

“Local treatment is typically going to consider some kind of surgery with or without radiation, depending on the surgery and the extent of the breast cancer. All women are going to have, and today when you use the word women, individuals assigned female at birth, they are the vast majority of individuals being treated for breast cancer, but for individuals assigned male at birth, there’s not near as much research, but generally their treatment is very similar. So that’s something to kind of keep in the back of your mind.” TS 2:39 

“This is very confusing for patients because they’re like, ‘Well, my friend at church had this and why am I getting this and why are they getting something different?’ And that is because of the pathology report. So taking that time to explain that with a pathology, I think is really important.” TS 8:31 

“When they see the breast surgeon, all individuals are going to have some kind of axillary evaluation.  Now, hopefully it’s going to be a sentinel lymph node. So they’re going to, at the time of surgery, put a tracer and, you know, they’re going to take out maybe one, two, three lymph nodes and hopefully, you know, there is not a lot of disease there. And if that’s the case, they’re kind of done with that. So the sentinel lymph node evaluation, it’s really more to stage and provide that information, but it kind of sets the stage a lot of times for the other treatments selections. And I think people need to realize that this is important. This is a very important procedure.” TS 15:31 

“Years ago, when women had a breast mass, they went to the OR and it was biopsied in a frozen section and if it was positive, they had a mastectomy. So women would wake up and they’d be feeling their chest because they’re like, ‘What happened here?’ And that is not great care. It doesn’t give that woman any autonomy, but it was the best that could be done at that point. Now, with the diagnostic where we can do a needle biopsy, they can kind of stop and take a timeout and we can kind of clinically stage that.” TS 17:04 

“For women that really desire breast-conserving therapy, they can anticipate that postoperatively at some point, they’re going to have treatment to the entire breast, we typically call whole breast radiation, and then they may have a boost. Now, in many, many probably cases, that’s going to be over five to six weeks, Monday through Friday. So the treatment itself doesn’t take but a couple of minutes, but you have to get to the facility. And even though we streamline check-in processes and whatnot, you have to get undressed, you have to get positioned on the table. So it is a commitment, and it can be disruptive.” TS 24:49 

“The hormone-blocking agents are going to be the cornerstone of all those treatments for anyone who has hormone receptor–positive breast cancer. So they are going to take these agents and as you said, they’re probably going to take them for 5–10 years. It’s quite the journey.” TS 32:33  

“I think you need to be mindful that if someone has had germline testing and they’ve tested positive, they are not only worried about themselves, and they are worried about the rest of their family. That is a big deal. And even though I’ll hear mothers say, ‘I feel so guilty, now my daughter has this,’ now, I’ve never heard a daughter come and say, ‘Gosh, I wish my mom hadn’t had me because of this.’ There’s a lot of feeling and emotion that goes on with that, and realize that those individuals are probably going to have fairly complicated management that goes over and above their breast cancer.” TS 41:50